Protocol Ledger

NCT05282121 · Phase II · TERMINATED

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal

Interventional Phase II clinical trial protocol NCT05282121 sponsored by Boehringer Ingelheim in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-28 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05282121
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05282121
Protocol FieldVerified Registry Value
NCT IdentifierNCT05282121
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2022-06-28
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI